Journal of Medical Cases, ISSN 1923-4155 print, 1923-4163 online, Open Access |
Article copyright, the authors; Journal compilation copyright, J Med Cases and Elmer Press Inc |
Journal website https://www.journalmc.org |
Case Report
Volume 12, Number 7, July 2021, pages 295-299
Osimertinib-Induced Unilateral Diffuse Alveolar Hemorrhage in a Patient With Pulmonary Adenocarcinoma
Figures
Table
Author (year) | EGFR-TKI (line) | Age (years), sex, country | Symptoms | Mutations | Intervala | Steroid use (initial dose) | Respiratory management | BFS (differential cell count) |
---|---|---|---|---|---|---|---|---|
aThe interval time from the start of EGFR-TKI to the onset of symptoms. EGFR-TKI: epidermal growth factor receptor tyrosine kinase inhibitor; Ex: exon; F: female; Gef: gefitinib; Lym: lymphocytes; M: male; mPSL: methylprednisolone; ND: not described; Neu: neutrophils; NPPV: non-invasive positive pressure ventilation; Osim: osimertinib; SQ: squamous carcinoma; BFS: bronchial fiberscope. | ||||||||
Ieki et al, 2003 [4] | Gef (4th) | 56 M, Japan | Dyspnea, bloody phlegm | ND | 4 weeks | High-dose mPSL | NPPV | Performed (90% Lym, 10% Neu) |
Yano et al, 2005 [5] | Gef (4th) | 62 F, Japan | ND | ND | 13 months | mPSL (1,000 mg/day) | ND | ND |
Zhao et al, 2014 [6] | Erl (1st) | 40 M, China | Fever | Esophageal carcinoma (SQ) | 1 month | mPSL (1,000 mg/day) | NPPV | Performed (ND) |
Sakoda et al, 2011 [8] | Gef (2nd) | 74 F, Japan | Epistaxis, bloody phlegm | ND | 2 weeks | No steroid | Nasal O2 | Performed (ND) |
Forte et al, 2019 [1] | Osim (multiple) | 65 F, USA | Dyspnea, fatigue | Ex19del,T790M | 5 months | mPSL (1,000 mg/day) | Intubated | Performed (ND) |
Komori et al, 2019 [7] | Osim (2nd) | 75 F, Japan | Bloody phlegm | L858R, T790M | 2 months | PSL (0.5 mg/kg) | ND | Performed (20% Lym, 8% Neu) |
Ours | Osim (1st) | 70 M, Japan | Dyspnea | Ex19del | 4 months | mPSL (1,000 mg/day) | Intubated | Performed (55% Lym, 44% Neu) |